Evidence map›Paper›PMID 41988850›Full record

ArticleHistopathology2026

Immunophenotypic assessment of pure embryonal carcinoma and yolk sac tumour suggests that reprogramming to non-seminoma occurs outside the spermatogonial niche.

Daisy Maharjan, Květoslava Michalová, Joao Lobo, Jennifer Gordetsky, Fiona MacLean, Ankur R Sangoi, Daniel Berney, Chia-Sui Kao, Costantino Ricci, Adeboye O Osunkoya and 6 more

Abstract read
In one paragraph

Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daisy MaharjanDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-8113-243X
Květoslava MichalováDepartment of Pathology, Charles University, Faculty of Medicine in Plzen, Biopticka Laborator, Ltd, Plzen, Czech Republic.ORCID https://orcid.org/0000-0003-3231-6870
Joao LoboDepartment of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0001-6829-1391
Jennifer GordetskyDepartment of Pathology and Urology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-0745-2160
Fiona MacLeanDouglass Hanly Moir Pathology, North Ryde, New South Wales, Australia.ORCID https://orcid.org/0000-0002-6468-2368
Ankur R SangoiDepartment of Pathology, Stanford Medical Center, Stanford, California, USA.ORCID https://orcid.org/0009-0007-7233-2361
Daniel BerneyCentre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0001-5474-8696
Chia-Sui KaoDepartment of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-6609-2567
Costantino RicciPathology Unit, DIAP-Dipartimento Interaziendale anatomia patologica di Bologna, Maggiore Hospital-AUSL Bologna, Bologna, Italy.
Adeboye O OsunkoyaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-5712-8134
Maria Rosaria RaspolliniDepartment of Pathology, University Hospital Careggi, Florence, Italy.ORCID https://orcid.org/0000-0001-6630-4881
Geert Jlh van LeendersDepartment of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID https://orcid.org/0000-0003-2176-9102
Muhammad T IdreesDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Lee Ann BaldridgeDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Thomas M UlbrightDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-7828-2496
Andres M AcostaDepartment of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0001-8817-6331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsGerm cell neoplasia in situ (GCNIS) is the precursor of GCNIS-derived testicular germ cell tumours, including seminomas and non-seminomas. Most non-seminomas show mixed histology, often including components of seminoma. A small subset presents as pure non-seminomatous germ cell tumors. In these neoplasms, the absence of invasive seminoma. raises the possibility that reprogramming to non-seminoma may occur at an early in-situ stage (i.e., within the spermatogonial niche). This study examined GCNIS associated with pure embryonal carcinoma (EC) and postpubertal-type yolk sac tumour (YST) using immunohistochemistry for transcription factors characteristic of GCNIS/seminoma, EC, and YST phenotypes to determine if reprogramming to non-seminoma occurs within the spermatogonial niche.

methodsGCNIS associated with pure testicular YST and EC was assessed using OCT4, FOXA2 (only YST), CD30 (only EC), SOX2 (only EC), SOX17, and NANOG immunohistochemistry. Adjacent foci of intratubular and invasive tumour were also evaluated, if present.

resultsSixty-seven pure non-seminomas (63 EC, 4 YST) were evaluated. In all cases, GCNIS expressed OCT4, SOX17, and NANOG. GCNIS associated with EC was consistently negative for CD30 and SOX2, and GCNIS associated with YST was consistently negative for FOXA2. Adjacent invasive EC (62/67 cases) and intratubular EC (19/67) showed the classic EC immunophenotype: OCT4+/NANOG+/SOX17-/SOX2+/CD30+. Similarly, invasive YST adjacent to GCNIS was OCT4-/NANOG-/SOX17+/FOXA2+.

conclusionsAssessment of transcription factors involved in the induction and maintenance of EC and YST phenotypes suggests that, in pure non-seminomas, reprogramming occurs outside the spermatogonial niche.

Indexed as

Carcinoma, EmbryonalCarcinoma in SituEndodermal Sinus TumorNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdolescentAdultBiomarkers, TumorCellular ReprogrammingHumansImmunohistochemistryImmunophenotypingMaleSpermatogoniaBiomarkers, Tumorembryonal carcinomagerm cell neoplasia in situimmunohistochemistryyolk sac tumour

Identifiers

PMID41988850
PMCPMC13341035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.